CL2024001560A1 - Radioligandos escindibles para dirigirse a receptores de la superficie celular y usos de los mismos. - Google Patents
Radioligandos escindibles para dirigirse a receptores de la superficie celular y usos de los mismos.Info
- Publication number
- CL2024001560A1 CL2024001560A1 CL2024001560A CL2024001560A CL2024001560A1 CL 2024001560 A1 CL2024001560 A1 CL 2024001560A1 CL 2024001560 A CL2024001560 A CL 2024001560A CL 2024001560 A CL2024001560 A CL 2024001560A CL 2024001560 A1 CL2024001560 A1 CL 2024001560A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- solvate
- cleavable
- pharmaceutically acceptable
- radioligands
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163283361P | 2021-11-26 | 2021-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001560A1 true CL2024001560A1 (es) | 2025-03-28 |
Family
ID=86540347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001560A CL2024001560A1 (es) | 2021-11-26 | 2024-05-23 | Radioligandos escindibles para dirigirse a receptores de la superficie celular y usos de los mismos. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12214059B2 (enExample) |
| EP (1) | EP4436979A4 (enExample) |
| JP (1) | JP2024542592A (enExample) |
| KR (1) | KR20240121775A (enExample) |
| CN (1) | CN118451091A (enExample) |
| CA (1) | CA3238734A1 (enExample) |
| CL (1) | CL2024001560A1 (enExample) |
| MX (1) | MX2024005950A (enExample) |
| WO (1) | WO2023097038A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018204872A2 (en) * | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
| EP4436979A4 (en) | 2021-11-26 | 2026-06-10 | Full Life Tech Uk Limited | Cleftable radioligands for targeting cell surface receptors and their uses |
| WO2024126687A1 (en) * | 2022-12-16 | 2024-06-20 | Silence Therapeutics Gmbh | Nucleic acids conjugated to an albumin binding moiety |
| EP4719486A1 (en) * | 2023-05-31 | 2026-04-08 | Full-Life Technologies UK Limited | Conjugates and uses thereof |
| EP4719498A1 (en) * | 2023-05-31 | 2026-04-08 | Full-Life Technologies UK Limited | Radioligands for targeting cell surface receptors and uses thereof |
| WO2025113628A1 (en) * | 2023-11-30 | 2025-06-05 | Full-Life Technologies Hk Limited | Sstr receptor targeting radio compounds and uses thereof |
| CN118240015B (zh) * | 2024-03-21 | 2025-03-21 | 中国科学院近代物理研究所 | 一种针对脑胶质瘤的靶向多肽及放射性示踪剂 |
| WO2026002208A1 (zh) * | 2024-06-28 | 2026-01-02 | 思路迪生物医药(上海)有限公司 | 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用 |
| WO2026080432A1 (en) * | 2024-10-07 | 2026-04-16 | Beth Israel Deaconess Medical Center, Inc. | Dimeric p-selectin inhibitors and uses thereof |
| CN121991166A (zh) * | 2024-11-05 | 2026-05-08 | 成都纽瑞特医疗科技股份有限公司 | 放射性配体化合物及其用途 |
| WO2026119233A1 (en) * | 2024-12-04 | 2026-06-11 | Full-Life Technologies Uk Limited | Conjugates and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| US8575123B2 (en) * | 2008-04-11 | 2013-11-05 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| EP4420730A3 (en) | 2009-03-19 | 2024-11-13 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
| ES2743482T3 (es) * | 2014-05-06 | 2020-02-19 | Univ Johns Hopkins | Inhibidores de PSMA marcados con metal/radiometal para obtención de imágenes dirigidas a PSMA y radioterapia |
| MX392700B (es) | 2016-08-10 | 2025-03-11 | Cancer Targeted Tech Llc | Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados. |
| KR102724812B1 (ko) * | 2017-04-05 | 2024-11-01 | 코넬 유니버시티 | 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물 |
| CA3060143A1 (en) * | 2017-05-24 | 2018-11-29 | Itm Isotopen Technologien Munchen Ag | Novel psma-binding agents and uses thereof |
| AU2018352731B2 (en) | 2017-10-22 | 2023-10-05 | Provincial Health Services Authority | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
| WO2019165200A1 (en) | 2018-02-22 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer |
| KR102156385B1 (ko) | 2018-03-30 | 2020-09-15 | (주)퓨쳐켐 | 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품 |
| WO2019246311A1 (en) | 2018-06-19 | 2019-12-26 | Lumiphore, Inc. | Macrocycle conjugates |
| ES3038393T3 (en) * | 2018-08-09 | 2025-10-13 | Hoffmann La Roche | Cleavable linker for peptide synthesis |
| US20200078478A1 (en) | 2018-09-10 | 2020-03-12 | Ming-Hsin Li | Structural molecule of peptide derivative for PSMA-targeting radiotherapy diagnosis and treatment |
| KR20210116437A (ko) | 2018-11-20 | 2021-09-27 | 코넬 유니버시티 | 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도 |
| WO2021046233A1 (en) | 2019-09-03 | 2021-03-11 | Cancer Targeted Technology Llc | Chelate-containing psma inhibitors |
| WO2021163498A1 (en) | 2020-02-14 | 2021-08-19 | Northwestern University | Retrograde neuronal tracers detectable by fluorescence and other imaging methods |
| TWI908773B (zh) * | 2020-03-04 | 2025-12-21 | 日商日本醫事物理股份有限公司 | 化合物及放射性標誌化合物 |
| JP7894086B2 (ja) | 2020-05-06 | 2026-07-23 | コーネル ユニヴァーシティー | 銅含有セラグノスティック化合物及びその使用の方法 |
| EP4436979A4 (en) | 2021-11-26 | 2026-06-10 | Full Life Tech Uk Limited | Cleftable radioligands for targeting cell surface receptors and their uses |
-
2022
- 2022-11-23 EP EP22899414.1A patent/EP4436979A4/en active Pending
- 2022-11-23 MX MX2024005950A patent/MX2024005950A/es unknown
- 2022-11-23 JP JP2024531425A patent/JP2024542592A/ja active Pending
- 2022-11-23 CN CN202280078538.7A patent/CN118451091A/zh active Pending
- 2022-11-23 CA CA3238734A patent/CA3238734A1/en active Pending
- 2022-11-23 WO PCT/US2022/050952 patent/WO2023097038A1/en not_active Ceased
- 2022-11-23 KR KR1020247021297A patent/KR20240121775A/ko active Pending
-
2024
- 2024-03-13 US US18/604,400 patent/US12214059B2/en active Active
- 2024-05-23 CL CL2024001560A patent/CL2024001560A1/es unknown
- 2024-12-03 US US18/967,265 patent/US12673122B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN118451091A (zh) | 2024-08-06 |
| US12214059B2 (en) | 2025-02-04 |
| EP4436979A1 (en) | 2024-10-02 |
| MX2024005950A (es) | 2024-08-06 |
| AU2022397307A1 (en) | 2024-06-06 |
| US20240382630A1 (en) | 2024-11-21 |
| JP2024542592A (ja) | 2024-11-15 |
| EP4436979A4 (en) | 2026-06-10 |
| KR20240121775A (ko) | 2024-08-09 |
| WO2023097038A1 (en) | 2023-06-01 |
| US20250099632A1 (en) | 2025-03-27 |
| US12673122B2 (en) | 2026-07-07 |
| CA3238734A1 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005950A (es) | Radioligandos escindibles para dirigirse a receptores de la superficie celular y sus usos. | |
| CL2021002883A1 (es) | Moduladores de thr-ß y métodos de uso de estos | |
| MX2021015221A (es) | Compuestos de aminobenzazepina, inmunoconjugados y usos de estos. | |
| PE20241299A1 (es) | Derivados de exatecan y sus conjugados anticuerpo-farmaco | |
| CL2020001133A1 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos. (divisional solicitud 201901664) | |
| PE20252338A1 (es) | Compuesto agonista de receptor thrb y metodo de preparacion | |
| MX2022004875A (es) | Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos. | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| BR112018077362A2 (pt) | conjugados para edição de superfície de célula-alvo | |
| UY30387A1 (es) | Nuevos compuestos | |
| UY37728A (es) | Nuevos enlazantes peptídicos y conjugados de criptoficina, su preparación y su uso terapéutico | |
| CL2023002578A1 (es) | Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos | |
| CL2023002322A1 (es) | Derivados de hidroxiheterocicloalquil-carbamoilo | |
| PE20250457A1 (es) | Compuestos antivirales y metodos de elaboracion y uso de los mismos | |
| MX2020004267A (es) | Sulfatos de alcoholes secundarios alcoxilados. | |
| MX2023006799A (es) | Inmunoconjugados anti-cea y usos de estos. | |
| MX2019007670A (es) | Nuevos antioxidantes para cosmeticos y composiciones farmaceuticas que contienen eteres alquilicos de glicerol. | |
| DOP2022000073A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| CO2024010726A2 (es) | Compuestos heterocíclicos y métodos de uso | |
| AR056025A1 (es) | Compuestos de imidazol sustituidos como inhibidores de ksp | |
| DOP2025000090A (es) | Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina | |
| CO2025015888A2 (es) | Compuestos y formulaciones adyuvantes útiles en vacunas neumocócicas | |
| CL2022000892A1 (es) | Derivados de 2–azaespiro[3.4]octano como agonistas de m4 | |
| AR060690A1 (es) | Polimeros que contienen magnesio para la hiperfosfatemia | |
| AR053678A1 (es) | Compuestos farmaceuticamente activos, su manufactura, composiciones que los contienen y su uso |